Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study
05/08/2025 14:50
Aug 5 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE THERAPEUTICS INC - ANNOUNCES INTERIM ANALYSIS OF ISTAROXIME PHASE 2 STUDY - SEC FILING WINDTREE THERAPEUTICS INC - ISTAROXIME ADDED TO INOTROPES, NO NEW SAFETY SIGNALS - SEC FILING WINDTREE THERAPEUTICS INC - DATA SUPPORTS MOVING FORWARD WITH GLOBAL PHASE 3 TRIAL - SEC FILING Further company coverage: WINT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study